The CROSSER System is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions. The device is contraindicated for use in carotid arteries.

The CROSSER Catheter is only intended for use with the CROSSER Electronics System. Refer to the CROSSER Electronics System Manual of Operations for proper use.

Device Description

The CROSSER System consists of a re-usable electronic Generator, Foot Switch, highfrequency Transducer, and single-use CROSSER Catheter. The CROSSER Catheter is available in three sizes:

CROSSER 14P (014 guidewire compatible), .
CROSSER 14S (014 guidewire compatible supportive), .
CROSSER 18 (018 guidewire compatible). .

Each Catheter is connected to the electronic Generator through the Transducer. The Foot Switch is used to activate the system. The Generator and Transducer convert AC power into high-frequency mechanical vibrations which are propagated through a Nitinol core wire to the Titanium tip of the CROSSER Catheter. The main body of the catheter is constructed from Pebax and a hydrophilic coating which covers the distal end of the catheter.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study for the CROSSER System, as much as can be extracted from the given document:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria Category	Specific Test/Characteristic	Acceptance Criteria (Implied)	Reported Device Performance
Physical Test Data	Tensile Strength	Met relevant guidance documents	Performed similarly to predicate device
	Torque Strength	Met relevant guidance documents	Performed similarly to predicate device
	Torqueability	Met relevant guidance documents	Performed similarly to predicate device
	Tip Flexibility	Met relevant guidance documents	Performed similarly to predicate device
	Coating Adherence/Integrity	Met relevant guidance documents	Performed similarly to predicate device
	Biocompatibility	Met relevant guidance documents	Performed similarly to predicate device
	Benchtop Simulated Efficiency	Met relevant guidance documents	Performed similarly to predicate device
	Catheter Fatigue Testing	Met relevant guidance documents	Performed similarly to predicate device
	Shelf Life and Package Integrity Testing	Met relevant guidance documents	Performed similarly to predicate device
	Dimensional Verification	Met relevant guidance documents	(Implied to be met for substantial equivalence)
Clinical Test Data	Intended Use	Facilitate intra-luminal placement of guidewires beyond peripheral artery CTOs.	"The clinical performance of the CROSSER System was verified through a human clinical study designed to demonstrate the intended use of the device." (Specific performance metrics are not detailed in this summary.)

Important Note: The document heavily relies on "performed similarly to the predicate device" and "met the acceptance criteria" without explicitly stating numerical or qualitative thresholds for each specific test. This is common in 510(k) summaries where detailed raw data and specific thresholds are typically in the full submission, not the public summary.

2. Sample Size for the Test Set and Data Provenance

Sample Size for Test Set: The document mentions "a human clinical study" but does not specify the sample size for this study.
Data Provenance: The document does not specify the country of origin of the data. It indicates the study was a "human clinical study," implying prospective human data.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

The document does not provide any information about experts used to establish ground truth in the clinical study, nor their number or qualifications. Given the nature of the device (facilitating guidewire placement), the primary "ground truth" would likely be successful guidewire crossing and subsequent procedural outcomes, observed and documented by the interventionalists performing the procedures.

4. Adjudication Method for the Test Set

The document does not describe any adjudication method.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. The device is not an imaging AI diagnostic system that would typically involve a multi-reader study. The clinical study was designed to verify the performance of the device itself in facilitating guidewire placement.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done

This question is not applicable to the CROSSER System. The device is a physical medical device (catheter system), not a standalone algorithm. Its function is to be used with a human operator (interventionalist).

7. The Type of Ground Truth Used

The ground truth for the clinical study was likely procedural success and outcomes data. The "intended use" of the device is to facilitate guidewire placement beyond peripheral artery chronic total occlusions. Therefore, a successful outcome would be the ability to achieve this objective. This would be clinical observation by the treating physicians, rather than pathology or expert consensus on image interpretation.

8. The Sample Size for the Training Set

The document does not mention or imply a "training set" as this is not an AI/machine learning device. The design, bench, and biocompatibility testing inform the device's development (analogous to "training" in a broad sense), but there isn't a specific data set called a "training set" in the context of this traditional device submission.

9. How the Ground Truth for the Training Set Was Established

This question is not applicable as there is no "training set" in the context of an AI/machine learning algorithm for which ground truth would be established. The "ground truth" for the device's design and manufacturing revolves around meeting established engineering, material science, and safety standards during its development.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the text "FLOWCARDIA, INC." in a bold, sans-serif font. There are two horizontal lines below the text. To the right of the text, there is a sine wave pattern.

5) 510(k) Summary

This summary of 510(k) information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21CFR807.92.

510(k) Number K072776

Applicant Information
Date Prepared:	September 27, 2007
Name and Address:	FlowCardia, Inc.

・・ 2007 ្រីក

	745 N. Pastoria Avenue
	Sunnyvale, CA 94085
	Ph: (408) 617-0352
Contact Person:	Dustin Michaels, Sr. Director of RA/CF
	Ph: (408) 617-0352 x302
	Fax: (408) 617-9198

Device Information

Classification:	DQY
Trade Name:	The CROSSER System
Common Name:	Percutaneous Catheter
Classification Name:	Percutaneous Catheter, 74 DQY / 21 CFR 870.1250

Predicate Device

The CROSSER System manufactured by FlowCardia, Inc. (K062868)

Indications for Use:

The CROSSER Catheter is only intended for use with the CROSSER Electronics System. Refer to the CROSSER Electronics System Manual of Operations for proper use.

{1}------------------------------------------------

Device Description

The CROSSER System consists of a re-usable electronic Generator, Foot Switch, highfrequency Transducer, and single-use CROSSER Catheter. The CROSSER Catheter is available in three sizes:

CROSSER 14P (014 guidewire compatible), .
CROSSER 14S (014 guidewire compatible supportive), .
CROSSER 18 (018 guidewire compatible). .

Technological Characteristics

The predicate and CROSSER System catheters are substantially equivalent with respect to materials, design construction and performance. The CROSSER System catheters differ only slightly with respect to tip diameter, tip material and guidewire lumen length. These differences are due to the intended use of the CROSSER Catheters over the predicate device; the predicate device is indicated for use in coronary chronic occlusions and the CROSSER System is indicated for use in peripheral artery occlusions.

Physical Test Data

Design analysis, bench, and biocompatibility testing were conducted according to the relevant guidance documents to demonstrate that the FlowCardia CROSSER System met the acceptance criteria and performed similarly to the predicate device. In addition to dimensional verification, the following functional tests were performed: Tensile Strength, Torque Strength, Torqueability, Tip Flexibility, Coating Adherence/Integrity, Biocompatibility, Bench top Simulated Efficiency, Catheter Fatigue Testing, Shelf Life and Package Integrity Testing.

Clinical Test Data

The clinical performance of the CROSSER System was verified through a human clinical study designed to demonstrate the intended use of the device.

Conclusion

Based upon device physical and clinical comparisons the CROSSER System is substantially equivalent to the predicate device.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

FlowCardia, Inc. Mr. Dustin Michaels Senior Director of RA/CR 745 N. Pastoria Avenue Sunnyvale, CA 94085

SEP 1 8 2013

Re: K072776

Trade/Device Name: The CROSSER System Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: PDU Dated: September 27, 2007 Received: September 28, 2007

Dear Mr. Michaels:

This letter corrects our substantially equivalent letter of December 7, 2007.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

{3}------------------------------------------------

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYowIndustry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Zm.z-

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Statement of Indications for Use

510(k) Number (if known):

K072776

Devicc Name:

The CROSSER System

Indications for Use:

The CROSSER Catheter is only intended for use with the CROSSER Electronics System. Refer to the CROSSER Electronics System Manual of Operations for proper use.

Prescription Use X (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Duna R. Vc Ames

(Division Sir. .off)
Division ci Cardiovascular Devices

510(k) number K072776

Regulation Number and Section

§ 870.1250 Percutaneous catheter.

(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).